样式: 排序: IF: - GO 导出 标记为已读
-
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 L. A. A. P. Derikx, F. Hoentjen
LINKED CONTENTThis article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and https://doi.org/10.1111/apt.17993
-
Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Ayesha Shah, Gerald Holtmann
LINKED CONTENTThis article is linked to Ricciuto et al paper. To view this article, visit https://doi.org/10.1111/apt.17936
-
Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Luciano Revelli, Melisa Dirchwolf
LINKED CONTENTThis article is linked to Mücke et al paper. To view this article, visit https://doi.org/10.1111/apt.17899
-
Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W. Leong
SummaryBackgroundThe expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real‐world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial
-
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 María José García, Javier P. Gisbert, María Chaparro
LINKED CONTENTThis article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and https://doi.org/10.1111/apt.17973
-
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
SummaryBackgroundRecently, a panel of multi‐society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction‐associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD).AimsWe compared the impact of SLD, subtype of SLD, MAFLD and NAFLD on all‐cause and cause‐specific mortality.MethodsA total of 7811 individuals in the third National
-
Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Nina Løn, Sara Engel, Anders Damholt, Anja Wellejus, Filip K. Knop
LINKED CONTENTThis article is linked to Løn et al papers. To view these articles, visit https://doi.org/10.1111/apt.17817 and https://doi.org/10.1111/apt.17984
-
Letter: Bif195 for aspirin‐induced gastric mucosal damage—More to do in further research Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Yuxin Wang, Wenwan Peng, Mingguo Dong
LINKED CONTENTThis article is linked to Løn et al papers. To view these articles, visit https://doi.org/10.1111/apt.17817 and https://doi.org/10.1111/apt.18002
-
Editorial: Adequate protein intake is more crucial than the profile of amino acids intake for sarcopenia prevention during the earlier stages of liver cirrhosis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Meropi D. Kontogianni
LINKED CONTENTThis article is linked to Hey et al paper. To view this article, visit https://doi.org/10.1111/apt.17917
-
Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Leya Nedumannil, Mustafa Mohamedrashed, Siddharth Sood, Diana Lewis
LINKED CONTENTThis article is linked to Vaishnav et al papers. To view these articles, visit https://doi.org/10.1111/apt.17868 and https://doi.org/10.1111/apt.17982
-
Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Hirokazu Takahashi, Miwa Kawanaka, Yoshio Sumida, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki
SummaryAimsA multi‐stakeholder consensus has proposed MASLD (metabolic dysfunction‐associated steatotic liver disease). We aimed to investigate the pathological findings related to the mid‐term mortality of patients with biopsy‐proven MASLD in Japan.MethodsWe enrolled 1349 patients with biopsy‐proven MASLD. The observational period was 8010 person years. We evaluated independent factors associated
-
Editorial: Crystalising the burden of steatotic liver disease—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Carolin V. Schneider, Kai Markus Schneider, Rohit Loomba
LINKED CONTENTThis article is linked to Schneider et al papers. To view these articles, visit https://doi.org/10.1111/apt.17958 and https://doi.org/10.1111/apt.17986
-
-
Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long‐term adverse outcomes in Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Agnès Fernández‐Clotet, Ingrid Ordás, Maria Carme Masamunt, Berta Caballol, Sonia Rodríguez, Marta Gallego, Rebeca Barastegui, Anny Carolina Saavedra, Julián Panés, Elena Ricart, Jordi Rimola
SummaryBackground and AimsMagnetic resonance enterography (MRE) depicts transmural changes in response to biological treatment for Crohn's disease (CD); however, the long‐term prognostic significance of these findings is unknown. The primary objective of this study was to identify findings on MRE 46 weeks after initiating biological treatment that predict adverse long‐term outcomes.MethodsPatients
-
Editorial: Are glucagon‐like peptide‐1 receptor agonists the functional cure for patients with metabolic dysfunction‐associated cirrhosis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Elton Dajti, Susana G. Rodrigues
LINKED CONTENTThis article is linked to Elsaid et al paper. To view this article, visit https://doi.org/10.1111/apt.17925
-
Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Dominik Bettinger, Robert Thimme, Lukas Sturm
LINKED CONTENTThis article is linked to Yoon et al paper. To view this article, visit https://doi.org/10.1111/apt.17909
-
Editorial: Crystalising the burden of steatotic liver disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Luis Calzadilla Bertot, Leon A. Adams
LINKED CONTENTThis article is linked to Schneider et al papers. To view these articles, visit https://doi.org/10.1111/apt.17958 and https://doi.org/10.1111/apt.17992
-
Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-22 Stephanie A. Vuijk, Maria M. E. Jongsma, Britt M. Hoeven, Maarten A. Cozijnsen, Merel van Pieterson, Tim G. J. de Meij, Obbe F. Norbruis, Michael Groeneweg, Victorien M. Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick F. van Rheenen, Michiel P. van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J. Poley, Johanna C. Escher, Lissy de Ridder
SummaryBackgroundData on cost‐effectiveness of first‐line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed.AimTo investigate the cost‐effectiveness of first‐line infliximab compared to conventional treatment in children with moderate‐to‐severe Crohn's disease.MethodsWe
-
Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Paul Henderson
-
Editorial: Foretelling the future—Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Siri A. Urquhart, Joel G. Fletcher, David H. Bruining
-
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Enrico N. De Toni, Julia Mayerle, Bettina Oehrle, Max Seidensticker, Lorenza Rimassa, Alexander Philipp, Daniel Roessler, Najib Ben Khaled
-
Editorial: High qHBsAg—is it a good or bad signal? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Beom Kyung Kim
-
Editorial: Peering through the fog—New tools to assess neurocognitive symptoms in coeliac disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Javier A. Villafuerte Gálvez, Daniel A. Leffler
-
Editorial: Enriching our understanding of MASLD through representation of under‐reported populations Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Niharika Samala, Eduardo Vilar‐Gomez
-
Letter: Risks of proton pump inhibitor treatment in cirrhotic patients Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Jiamei Wang, Feng Wen, Jian Zhao
-
Letter: The enigma of angiotensin receptor blocker‐associated enteropathy Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Mustafa Mohamedrashed, Leya Nedumannil, Mayur Garg
-
Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Shinji Okabayashi, Taku Kobayashi
-
Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Basile Njei, Joseph K. Lim
-
Editorial: Can dietary gluten restriction improve hepatic steatosis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Hariklia Kranidioti, Melanie Deutsch
-
Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Jian Wang, Yifan Pan, Ye Xiong, Chao Wu, Rui Huang
-
Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 John E. Eaton, Sudhakar K. Venkatesh
-
Diagnostic yield from symptomatic lower gastrointestinal endoscopy in the UK: A British Society of Gastroenterology analysis using data from the National Endoscopy Database Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-18 David Beaton, Linda Sharp, Liya Lu, Nigel Trudgill, Mo Thoufeeq, Brian Nicholson, Peter Rogers, James Docherty, Anna Jenkins, A. John Morris, Thomas Rösch, Matthew Rutter
SummaryBackgroundThe value of lower gastrointestinal endoscopy (LGIE; colonoscopy or sigmoidoscopy) relates to its ability to detect clinically relevant findings, predominantly cancers, preneoplastic polyps or inflammatory bowel disease. There are concerns that many LGIEs are performed on low‐risk patients with limited benefit.AimsTo determine the diagnostic outcomes of LGIE for common symptoms.MethodsWe
-
Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-17 Maria Mironova, Harish Gopalakrishna, Gracia Maria Viana Rodriguez, Nehna Abdul Majeed, Asif A. Hitawala, Ivan J. Fuss, Jenna R. E. Bergerson, Alison J. Faust, Jacqueline M. Laurin, Jaha Norman‐Wheeler, Shani Scott, Julian Hercun, Bernadette Redd, David E. Kleiner, Christopher Koh, Theo Heller
SummaryBackgroundNon‐cirrhotic portal hypertension (NCPH) is a spectrum of liver diseases, including porto‐sinusoidal vascular disorder, with portal hypertension (PH) in the absence of cirrhosis. The natural history and diagnostic approach to NCPH are not well understood.AimWe aimed to evaluate disease progression and outcomes in NCPH.MethodsPatients with or at risk for NCPH were enrolled in a single
-
Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-14 Kyuwon Kim, Jae Jun Park, Hyuk Yoon, Jun Lee, Kyeong Ok Kim, Eun Sun Kim, Su Young Kim, Sun-Jin Boo, Yunho Jung, Jun Hwan Yoo, Sung Wook Hwang, Sang Hyoung Park, Suk-Kyun Yang, Byong Duk Ye
-
Crohn's disease after surgery: Changes in post‐operative management strategies over time and their impact on long‐term re‐operation rate—A retrospective multicentre real‐world study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-15 Annalisa Aratari, Maria Lia Scribano, Daniela Pugliese, Valentina Baccolini, Fabiola De Biasio, Serena Verna, Chiara Morretta, Stefano Festa, Alessandro Armuzzi, Claudio Papi
-
Paediatric‐onset immune‐mediated inflammatory disease is associated with an increased mortality risk—A nationwide study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-10 Mikkel Malham, Sabine Jansson, Helene Ingels, Marianne Hørby Jørgensen, Naja Hulvej Rod, Vibeke Wewer, Matthew P. Fox
-
-
Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Arta Aliu, Daan H. C. A. Bosch, Daniel Keszthelyi, Ashkan Rezazadeh Ardabili, Jean‐Frederic Colombel, Rachel Sawyer, Hans Törnblom, Ailsa Hart, Daisy M. A. E. Jonkers, Marieke J. Pierik, Zlatan Mujagic
-
Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Matthew J. Townsend, Isaac J. Benque, Michael Li, Shilpa Grover
-
Editorial: Recompensation in PBC is good. But is it good enough? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Xavier Verhelst
LINKED CONTENTThis article is linked to Hofer et al papers. To view these articles, visit https://doi.org/10.1111/apt.17908 and https://doi.org/10.1111/apt.17966
-
Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Benedikt Silvester Hofer, Lukas Burghart, Emina Halilbasic, Benedikt Simbrunner, Oleksandr Petrenko, Mattias Mandorfer, Albert Friedrich Stättermayer, Michael Trauner, Thomas Reiberger
LINKED CONTENTThis article is linked to Hofer et al papers. To view these articles, visit https://doi.org/10.1111/apt.17908 and https://doi.org/10.1111/apt.17924
-
Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms–still a long way to go… Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Sabine Roman, François Mion
LINKED CONTENTThis article is linked to Calabrese et al papers. To view these articles, visit https://doi.org/10.1111/apt.17934 and https://doi.org/10.1111/apt.17960
-
Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply' Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Francesco Calabrese, Andrea Pasta, Giorgia Bodini, Manuele Furnari, Patrizia Zentilin, Edoardo G. Giannini, Daria Maniero, Domenico Della Casa, Giovanni Cataudella, Marzio Frazzoni, Roberto Penagini, Arsiè Elena, Nicola De Bortoli, Pierfrancesco Visaggi, Vincenzo Savarino, Edoardo Savarino, Elisa Marabotto
LINKED CONTENTThis article is linked to Calabrese et al papers. To view these articles, visit https://doi.org/10.1111/apt.17934 and https://doi.org/10.1111/apt.17955
-
Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Jakob B. Seidelin
LINKED CONTENTThis article is linked to Bokemeyer et al paper. To view this article, visit https://doi.org/10.1111/apt.17926
-
Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Iris Barth, Corien L. Stevens, Colette J. Strokap, Marjo J. E. Campmans‐Kuijpers, Arno R. Bourgonje, Gerard Dijkstra
LINKED CONTENTThis article is linked to Faqerah et al paper. To view this article, visit https://doi.org/10.1111/apt.17720
-
Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Jianrong Li, Dalong Yang, Jianhong Zhong, Yingyang Liao
LINKED CONTENTThis article is linked to Kang et al paper. To view this article, visit https://doi.org/10.1111/apt.17862
-
Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Jian Wang, Shaoqiu Zhang, Zhiyi Zhang, Chao Wu, Rui Huang
LINKED CONTENTThis article is linked to Sandmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17878 and https://doi.org/10.1111/apt.17962
-
Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Lisa Sandmann, Heiner Wedemeyer, Katja Deterding
LINKED CONTENTThis article is linked to Sandmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17878 and https://doi.org/10.1111/apt.17923
-
Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Leya Nedumannil, Mustafa Mohamedrashed, Anuj Bohra, Siddharth Sood, Diana Lewis
LINKED CONTENTThis article is linked to Thwaites et al papers. To view these articles, visit https://doi.org/10.1111/apt.17944 and https://doi.org/10.1111/apt.17970
-
Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease. Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-09 Phoebe A. Thwaites, Peter R. Gibson
LINKED CONTENTThis article is linked to Thwaites et al papers. To view these articles, visit https://doi.org/10.1111/apt.17944 and https://doi.org/10.1111/apt.17946
-
A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-08 Nikita Mittal, Harris Siddiqi, Egbert Madamba, Lisa Richards, Ricki Bettencourt, Veeral Ajmera, Rohit Loomba
-
Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-04 Nabil Noureddin, Daniel Q. Huang, Ricki Bettencourt, Harris Siddiqi, Abdul M. Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem Kuru Oz, Ayse Erden, Tolga Gidener, Alina M. Allen, Veeral Ajmera, Rohit Loomba
-
Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-04 Palak J. Trivedi, Katherine Arndtz, Nadir Abbas, Alison Telford, Liam Young, Rajarshi Banerjee, Peter Eddowes, Kartik S. Jhaveri, Gideon M. Hirschfield
SummaryBackgroundImaging markers of biliary disease in primary sclerosing cholangitis (PSC) have potential for use in clinical and trial disease monitoring. Herein, we evaluate how quantitative magnetic resonance cholangiopancreatography (MRCP) metrics change over time, as per the natural history of disease.MethodsIndividuals with PSC were prospectively scanned using non‐contrast MRCP. Quantitative
-
Review article: Telecare in gastroenterology—Within the COVID‐19 pandemic and beyond Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-01 Fatima Hakak, Rajan N. Patel, Richard B. Gearry
-
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-27 Mohamed I. Elsaid, Na Li, Stephen A. Firkins, Vinod K. Rustgi, Electra D. Paskett, Chathur Acharya, K. Rajender Reddy, Chien Wei Chiang, Khalid Mumtaz
-
Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-27 Timothy McAuliffe, Joseph C. Anderson, Robin J. Larson, Douglas J. Robertson
-
The epidemiology and management of Clostridioides difficile infection—A clinical update Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-27 Lindsay M. Clarke, Jessica R. Allegretti
-
Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 Jian Wang, Tao Fan, Shaoqiu Zhang, Chao Wu, Rui Huang
LINKED CONTENTThis article is linked to Hong et al papers. To view these articles, visit https://doi.org/10.1111/apt.17819 and https://doi.org/10.1111/apt.17937
-
Letter: Thioguanine, an underutilised option in inflammatory bowel disease? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 John D. Chetwood, Sudarshan Paramsothy, Rupert W. Leong
LINKED CONTENTThis article is linked to Vasudevan et al papers. To view these articles, visit https://doi.org/10.1111/apt.17831 and https://doi.org/10.1111/apt.17957
-
Editorial: Muscles at the expense of liver injury. Is it worth it? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 C. Stephens
LINKED CONTENTThis article is linked to Nash et al paper. To view this article, visit https://doi.org/10.1111/apt.17906